BEDFORD, Ohio, Sept. 7 /PRNewswire/ -- Bedford Laboratories is excited to announce they have further diversified their product offerings with the addition of pre-filled syringes. FDA approval has been granted and Sumaptriptan Succinate Injection, 6mg (base)/0.5 mL pre-filled syringes are now available. This is a very important product addition to their expanding portfolio of products. Sumaptriptan Succinate Injection is indicated for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache episodes. The product is AP rated to Imitrex®
(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.
Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. and a member of the Boehringer Ingelheim group of companies. For more information on Bedford Laboratories, visit www.bedfordlabs.com.
Imitrex® is a registered trademark of GlaxoSmithKline
SOURCE Bedford Laboratories
